Zenas BioPharma, Inc. (ZBIO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 29.41 |
| Open | 29.36 |
| Day High | 29.58 |
| Day Low | 27.52 |
| 52-Week High | 44.6 |
| 52-Week Low | 12.8 |
| Volume | 874,474 |
| Average Volume | 735,832 |
| Market Cap | 1.26B |
| PE | -5.61 |
| EPS | -5.03 |
| Moving Average 50 Days | 21.49 |
| Moving Average 200 Days | 25.3 |
| Change | -1.17 |
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
GlobeNewswire Inc.
Feb 09, 2026 12:05 PM GMT
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the robust and durable activity of obex
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:05 PM GMT
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformat
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
GlobeNewswire Inc.
Jan 05, 2026 12:05 PM GMT
- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four key second